Skip to Content

Nitisinone Dosage

Applies to the following strength(s): 10 mg ; 2 mg ; 5 mg ; 4 mg/mL

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Hereditary Tyrosinemia Type 1

Initial dose: 1 mg/kg/day divided into a morning and evening dose
Maintenance dose: 1 to 2 mg/kg/day divided into two daily doses
Maximum dose: 2 mg/kg/day

Comments: Requires dietary restriction of tyrosine and phenylalanine

Usual Pediatric Dose for Hereditary Tyrosinemia Type 1

Initial dose: 1 mg/kg/day divided into a morning and evening dose
Maintenance dose: 1 to 2 mg/kg/day divided into two daily doses
Maximum dose: 2 mg/kg/day

Comments: Requires dietary restriction of tyrosine and phenylalanine

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

In patients whose erythrocyte PBG-synthase activity and urine 5-ALA and urine succinylacetone are not normalized within one month after starting treatment, the dose may be increased to 1.5 mg/kg/day.

In patients receiving 1.5 mg/kg/day, whose erythrocyte PBG-synthase activity and urine 5-ALA and urine succinylacetone remain elevated and whose plasma succinylacetone is not normalized after three months, the dose may be increased up to a maximum dose of 2 mg/kg/day.

Precautions

Consult WARNINGS section for dosing related precautions

Dialysis

Data not available

Other Comments

Administration advice:
-Take one hour before or two hours after a meal
-Capsules may be opened and the contents suspended in a small amount of water immediately before use

Storage requirements: Refrigerate

General: Treatment should be initiated by a physician experienced in the treatment of Hereditary Tyrosinemia Type 1 (HT-1)

Monitoring: Plasma nitisinone concentration, plasma succinylacetone, urine 5-ALA and erythrocyte PBG-synthase activity, if not available, clinical laboratory assessments should include urine succinylacetone, liver function tests, alpha-fetoprotein, and serum tyrosine and phenylalanine level.

Patient advice:
-Maintain dietary restriction of tyrosine and phenylalanine during treatment
-Promptly report unexplained eye symptoms, rash, jaundice or excessive bleeding

Hide